Rapid, early vision gains with EYLEA® are maintained through Year 1 in CRVO1,2 and BRVO,3 and Year 2 in CRVO4

START STRONG with rapid, early visions gains in Year 1 of up to +17.1 letters in RVO1-3

RVO Year 1 & 2 gains GALLILEO, COPERNICUS & VIBRANT

STAY STRONG with vision gains of +13.0 letters maintained through Year 24

CRVO COPERNICUS Results: Mean change in BCVA Graph

BCVA, best-corrected visual acuity; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; ETDRS, Early Treatment Diabetic Retinopathy Study; PRN, pro re nata; RCT, randomized controlled trial; RVO, retinal vein occlusion; SD, standard deviation.

References

  1. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology. 2014;121(1):202-208.
  2. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(3):429-437.
  3. Clark WL, Boyer DS, Heier JS, et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology. 2016;123(2):330-336.
  4. Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414-1420.